GHK-Cu and Collagen: What a Randomised Human Trial Found

GHK-Cu (copper tripeptide) has been studied in human skin since the late 1990s. The most cited human evidence comes from a randomised trial published by Abdulghani et al. comparing topical copper peptide against tretinoin — the gold standard topical for skin remodelling — over a 12-week period.

The Human Trial

67 women with moderate-to-severe facial ageing were randomised to one of four topical treatment groups: GHK-Cu cream, vitamin C cream, melatonin cream, or tretinoin. Assessments at 4, 8, and 12 weeks included clinical evaluation and skin biopsies analysed for collagen density via immunohistology.

Key Results

• 70% of subjects in the GHK-Cu group showed measurable increases in collagen density — compared to 40% in the tretinoin group
• Improvements in skin laxity and fine lines were observed clinically in the GHK-Cu group
• GHK-Cu was better tolerated than tretinoin (which caused irritation in a subset of subjects)

Supporting Fibroblast Data

A 2001 study by McCormack et al. (PMID: 11176716) using a serum-free fibroblast model found that copper tripeptide reduced TGF-β1 secretion — suggesting a mechanism for reducing excessive scar and keloid formation — while simultaneously supporting collagen synthesis. This supports the in-vivo findings: GHK-Cu appears to remodel rather than simply stimulate collagen, potentially improving scar quality as well as skin density.

Mechanism

GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) with a high affinity for copper ions. It is present in human plasma and released after tissue injury. The copper complex activates pathways involved in wound healing, collagen synthesis, and tissue remodelling. Unlike growth factors that simply upregulate production, GHK-Cu appears to modulate the balance between synthesis and degradation.

Evidence Limitations

The Abdulghani 1998 trial was a pilot study in a specialised journal; it has been extensively cited in secondary literature but the original paper is difficult to access directly. The fibroblast data (McCormack 2001) is in vitro. The human collagen findings are suggestive, not definitive — a larger placebo-controlled RCT would strengthen the evidence base.